Clinical Study of Venetoclax with Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia

Clinical Study of Venetoclax with Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia

BackgroundAdults with relapsed/refractory acute myeloid leukemia (AML) have poor prognosis, very low long-term survival rate and cure rate, and limited chemotherapy regimens.ObjectiveTo investigate the safety and efficacy of venetoclax (VEN) with HAAG 〔homoharringtonine (HHT) , Cytarabine (Ara-C) ,...

Full description

Bibliographic Details
Main Author: CHEN Xiaofeng, WANG Meng, LI Zhongyu, LI Jiajia
Format: Article
Language:zho
Published: Chinese General Practice Publishing House Co., Ltd 2022-03-01
Series:Zhongguo quanke yixue
Subjects:
|leukemia, myeloid, acute|venetoclax|recurrence|drug therapy, combination|treatment outcome|antineoplastic combined chemotherapy protocols
Online Access:https://www.chinagp.net/fileup/1007-9572/PDF/yx2022012204.pdf

Internet

https://www.chinagp.net/fileup/1007-9572/PDF/yx2022012204.pdf

Similar Items